Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

GSK/NIH 'SAM' Strategy May Reap Benefits Beyond Zika

Executive Summary

GlaxoSmithKline PLC and the National Institute of Allergy and Infectious Diseases have entered into a partnership to develop a Zika vaccine based on the company's self-amplifying mRNA technology – a collaboration that could yield biomedical research and development benefits far beyond the current epidemic.


Related Content

Zika Vaccines Might Be Approved By 2020
Pandemic Vaccines Probably Can’t Use Accelerated Approval – US FDA Chief Scientist
Zika Vaccine Trials Could Test Multiple Candidates Vs. Common Control Group
Moderna's Valera Takes mRNA Approach To Combat Zika
Takeda In Hot Pursuit Of Zika Vaccine With $312m US Contract
Sanofi Teams With US Military On Zika, But Not For The Profits
Fauci: Borrowed Cash Won't Carry Zika Efficacy Trials
Congrats, Your Vaccine Works; Now, Who Will Buy It?
Pharma's Zika Pursuit: All About The Profits?
Fauci: Considerable Pharma Interest In Zika Vaccine


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Add a personalized Question to your Analyst